The Role of Exercise to Improve Physiological, Physical and Psychological Health Outcome in Idiopathic Inflammatory Myopathies (IIM)
DOI: https://doi.org/10.2147/jir.s377102
IF: 4.5
2024-06-06
Journal of Inflammation Research
Abstract:Karin Lodin, 1, 2, &ast Fabricio Espinosa-Ortega, 1, 2, &ast Ingrid E Lundberg, 1, 2 Helene Alexanderson 1, 3 1 Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; 2 Department of Gastro, Dermatology and Rheumatology, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden; 3 Medical Unit Allied Health Professionals, Theme Women's Health and Health Professionals, Karolinska University Hospital, Stockholm, Sweden &astThese authors contributed equally to this work Correspondence: Helene Alexanderson, Medical Unit Occupational Therapy and Physical Therapy, Theme Women's Health and Health Professionals, Karolinska University Hospital, Gävlegatan 55, NB02:00, Stockholm, 17176, Sweden, Email Idiopathic inflammatory myopathies (IIM) impact all aspects of health, physiological, physical, and psychological. Hallmark symptoms of IIM are muscle weakness, reduced muscle endurance and aerobic capacity. Recently, pain and fatigue as well as anxiety and depression have emerged as common and debilitating symptoms in patients with IIM. The aim of this scoping review is to, in a holistic way, describe how IIM impact patients' physiological, physical, and psychological health and how exercise has a role to treat as well as potentially counteract the effects of the disease. Inflammation induces non-immune response and organ damage. These changes with additional impact of physical inactivity lead to muscle impairment and reduced aerobic capacity. Pain, fatigue and low psychological well-being and overall quality of life are also common health aspects of IIM. Medical treatment can reduce inflammation but has in turn serious side effects such as muscle atrophy, type-II diabetes, and hypertension, which exercise has the potential to treat, and perhaps also counteract. In addition, exercise improves muscle function, aerobic capacity and might also reduce fatigue and pain. New evidence shows that reducing systemic inflammation may also improve patient-reported subjective health, quality of life and psychological well-being. Exercise in combination with medical treatment is becoming an important part of the treatment for patients with IIM as exercise has the potential to promote health aspects of various dimensions in patients with IIM. Keywords: exercise, idiopathic inflammatory myopathies, treatment The idiopathic inflammatory myopathies (IIM), or myositis, is an autoimmune, chronic disorder affecting skeletal muscle with clinical manifestations of muscle weakness and low muscle endurance. Myositis mainly affects proximal muscles in arms and legs as well as neck flexors leading to physiological, physical and psychological impairment negatively affecting quality of life and health. 1–4 Other organs are frequently involved such as joints, skin, lung, gastrointestinal tract and the heart, further negatively affecting outcome for patients with IIM. Treatment is based on high doses of glucocorticoids in combination with immunosuppressive drugs over a long period of time, often lasting for several years, and with disappointing results with persisting irreversible chronic manifestations such as muscle atrophy. 5 Side effects of the immunosuppressive treatment are common including osteoporosis with fractures, hypertension, diabetes and infections, further negatively affecting outcome and quality of life for patients with IIM. The IIM is a heterogeneous group of diseases and was in adult individuals previously subgrouped, based on clinical and histopathological differences, into dermatomyositis, polymyositis, and inclusion body myositis. More recently due to the advances in the discovery of several myositis specific autoantibodies several new subgroups have been identified: antisynthetase syndrome, immune mediated necrotizing myopathy, and amyopathic dermatomyositis. In addition, there is another subgroup called overlap myositis with features of myositis in combination with features of another defined autoimmune disorder, such as systemic sclerosis. 6 These subgroups vary in clinical presentation, treatment response and prognosis thus the recently identified subgroup, antisynthetase syndrome, has a high risk of a combination of myositis with arthritis and interstitial lung disease. 7 As the outcome varies between the IIM subgroups it is important to subclassify patients according to the combination of clinical manifestations, histopathology and serology. However, most published studies on outcome of IIM so far have been conducted in the "old" subgroups, polymyositis, dermatomyositis and inclusion body myositis which are likely to contain the new subgroups. A shared feature fo -Abstract Truncated-
immunology